RSS

high-risk

Plans have been announced by Sanofi and Regeneron to make Praluent (alirocumab) more accessible and affordable for those patients with the greatest health risk and unmet need. more

News

Despite it costing £1.8bn ($2.6bn) to bring a novel drug to market, pharmaceutical companies are increasingly looking towards developing first-in-class treatments to maximise revenue and stay ahead of competition, according to GBI Research more

News